[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"choroid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:choroid":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100637940","choroidal-and-retinal-features-in-pacd-and-poag-on-oct-and-octa-100637940",false,"NCT07580014","Choroidal and Retinal Features in PACD and POAG on OCT and OCTA","Inclusion Criteria:\n\n* Control group: Healthy individuals with no history of ocular surgery, IOP \\\u003C 21 mmHg, and CDR \\\u003C 0.5 bilaterally without asymmetry\n* Observation group: Glaucoma specialist-confirmed diagnosis of POAG or PACD (per ISGEO staging: PACS\u002FPAC\u002FPACG)\n\nExclusion Criteria:\n\n* History of retinal or macular disease (e.g., AMD, DR, RVO, ERM)\n* Non-glaucomatous optic neuropathy (e.g., MS, NMO)\n* Poor OCT\u002FOCTA image quality\n* Refusal to sign informed consent",true,"ALL","18 Years","90 Years",{"count":20,"type":21},132,"ESTIMATED","OBSERVATIONAL","Glaucoma is a group of irreversible, progressive optic neuropathies that can lead to severe visual field defects and even blindness, affecting nearly 95 million people worldwide. Based on anterior chamber angle structure, glaucoma is classified into primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG). Although POAG is more common, PACG is more severe and more likely to cause blindness if not managed appropriately. Globally, PACG accounts for approximately 25% of all glaucoma cases but is responsible for roughly 50% of glaucoma-related blindness. Generally, the term \"glaucoma\" implies optic nerve damage; however, glaucomatous optic neuropathy may be absent in subacute and acute angle-closure glaucoma. Therefore, according to international consensus, primary angle-closure disease is categorized as PACD-encompassing primary angle-closure suspect (PACS), primary angle closure (PAC), and PACG-based on the extent of angle closure, intraocular pressure elevation, and optic nerve damage. With advances in ophthalmic imaging, an increasing array of diagnostic modalities has been applied to glaucoma diagnosis. Optical coherence tomography (OCT), which utilizes low-coherence light to display cross-sectional images of the retina in vivo, represents a rapid, non-invasive, and continuously evolving imaging method. Building upon OCT, OCTA has emerged as a novel imaging technique that allows non-invasive visualization and assessment of blood flow in individual retinal layers \\[5\\]. Existing OCT and OCTA research on glaucoma primarily focuses on the optic disc and macula of glaucoma patients, providing evidence of changes in the retinal nerve fiber layer, macular ganglion cell thickness, optic nerve head structure, and peripapillary and macular vasculature. Other studies have examined choroidal vascular architecture and thickness in glaucoma; previous findings from our research group also indicate that choroidal vascular density is significantly lower in eyes with POAG and PACG compared to normal eyes, while choroidal stromal area is significantly greater in PACG than in POAG eyes and normal controls. Further investigation into choroidal and retinal alterations in glaucoma is warranted. Consequently, the OCT and OCTA fundus characteristics of patients with PACD and POAG remain an area with unexplored unknowns. This study utilizes OCT and OCTA to observe the choroidal and retinal tissue structure and vascular hemodynamics in patients with PACD and POAG, aiming to comprehensively investigate structural changes in the glaucomatous fundus, broaden new research directions, and explore and supplement the understanding of glaucoma pathogenesis.",[25,26,27],"Glaucoma","OCTA","Choroid","RECRUITING","2026-05-06",{"date":31,"type":32},"2026-05-12","ACTUAL",{"date":34,"type":32},"2024-07-16",{"date":36,"type":21},"2027-04-20",{"name":38,"class":39},"Zhongshan Ophthalmic Center, Sun Yat-sen University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":15,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100621852","effects-of-acute-sugar-intake-on-choroidal-thickness-100621852","NCT07376005","Effects of Acute Sugar Intake on Choroidal Thickness","Inclusion Criteria:\n\n* In order to be eligible for enrolment, each subject must have less than 6 diopters of spherical equivalent refractive error, and have no existing diagnosis of diabetes or pre-diabetes.\n\nExclusion Criteria:\n\n* Any potential subject with known retinal pathology will be excluded. Any potential subject with any other known systemic or ocular conditions that may impact their ability to participate in the study or provide generalizable data will also be excluded.","21 Years","35 Years",{"count":50,"type":21},47,"INTERVENTIONAL",[53],"NA","This study aims to bridge that gap by investigating how acute sugar intake influences choroidal thickness.",[27],"2026-01-21",{"date":58,"type":32},"2026-01-29",{"date":60,"type":21},"2026-01",{"date":62,"type":21},"2026-05",{"name":64,"class":39},"Southern College of Optometry"]